Efficacy of risankizumab in patients with moderate‐to‐severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa‐1 and UltIMMa‐2 studies

B. Strober, A. Menter, C. Leonardi, K. Gordon, J. Lambert, L. Puig, H. Photowala, M. Longcore, T. Zhan, P. Foley

Research output: Contribution to journalArticleResearchpeer-review

10 Citations (Scopus)
Original languageUndefined/Unknown
JournalJournal of the European Academy of Dermatology and Venereology
DOIs
Publication statusPublished - 3 Dec 2020

Cite this